Immunotherapy for Multiple Myeloma.

Area of Science:

• Oncology
• Immunology

Background:

• Multiple myeloma (MM) is a hematologic malignancy with a poor prognosis, especially in high-risk patients.
• Current treatments face limitations, necessitating novel therapeutic strategies.
• MM is characterized by immune dysregulation, including impaired T-cell, NK cell, and dendritic cell function.

Purpose of the Study:

• To review recent advances in immunotherapy for multiple myeloma.
• To highlight novel treatment strategies and their potential impact on patient outcomes.

Main Methods:

• Review of recent clinical trials and emerging immunotherapeutic approaches for MM.
• Analysis of novel antibody-based therapies, cellular therapies, and checkpoint inhibitors.

Main Results:

• Monoclonal antibodies (e.g., daratumumab) combined with immunomodulatory drugs have shown improved prognosis in advanced MM.
• Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen demonstrates efficacy.
• Ongoing trials explore antibody-drug conjugates, bispecific T-cell engagers, and checkpoint inhibitors (e.g., anti-TIGIT).

Conclusions:

• Emerging immunotherapies, including antibody-based treatments and CAR T-cell therapy, are significantly improving outcomes for MM patients.
• Combination therapies and novel approaches like checkpoint inhibition hold promise for further improving prognosis and potentially achieving a cure for MM.